Unknown

Dataset Information

0

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.


ABSTRACT: COVID-19-related mortality among hematopoietic stem cell transplantation (HSCT) recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech BNT162b2 vaccine demonstrated significant immunogenicity and efficacy in the healthy population; however, its long-term effects on allogeneic HSCT recipients remained unclear. Our study longitudinally evaluated humoral and cellular responses to the BNT162b2 vaccine in adult allogeneic HSCT patients. A positive response was defined as antibody titers ≥ 150 AU/mL post-second vaccination. Among 77 included patients, 51 (66.2%) responded to vaccination. Response-associated factors were female gender, recent anti-CD20 therapy, and a longer interval between transplant and vaccination. Response rates reached 83.7% in patients vaccinated >12 months post-transplant. At 6 months post-second vaccination, antibody titers dropped, but were significantly increased with the booster dose. Moreover, 43% (6/14) of non-responders to the second vaccination acquired sufficient antibody titers after booster administration, resulting in an overall response rate of 79.5% for the entire cohort. The BNT162b2 vaccine was effective in allogeneic transplant recipients. Although antibody titers decreased with time, the third vaccination led to their significant elevation, with 93% of third-dose responders maintaining titers above 150 AU/mL at 3 months post-administration.

SUBMITTER: Henig I 

PROVIDER: S-EPMC10145595 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Third BNT162b2 mRNA SARS-CoV-2 Vaccine Dose Significantly Enhances Immunogenicity in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation.

Henig Israel I   Isenberg Jonathan J   Yehudai-Ofir Dana D   Leiba Ronit R   Ringelstein-Harlev Shimrit S   Ram Ron R   Avni Batia B   Amit Odelia O   Grisariu Sigal S   Azoulay Tehila T   Slouzkey Ilana I   Zuckerman Tsila T  

Vaccines 20230331 4


COVID-19-related mortality among hematopoietic stem cell transplantation (HSCT) recipients in the pre-vaccine era ranged between 22 and 33%. The Pfizer/BioNTech BNT162b2 vaccine demonstrated significant immunogenicity and efficacy in the healthy population; however, its long-term effects on allogeneic HSCT recipients remained unclear. Our study longitudinally evaluated humoral and cellular responses to the BNT162b2 vaccine in adult allogeneic HSCT patients. A positive response was defined as ant  ...[more]

Similar Datasets

| S-EPMC9383557 | biostudies-literature
| S-EPMC10892348 | biostudies-literature
| S-EPMC9015954 | biostudies-literature
| S-EPMC9506309 | biostudies-literature
| S-EPMC8415894 | biostudies-literature
| S-EPMC9570131 | biostudies-literature
| S-EPMC8397500 | biostudies-literature
| S-EPMC9316698 | biostudies-literature
| S-EPMC11867918 | biostudies-literature